Table 1.

General features of the study population and their clinical parameters.

Demographics parameters and clinical scores	# of patients
Sex (F/M)	43 (67.19)/21 (32.81)
Age (years)	37 [19.0–61.0]
Age at onset (years)	32 [14.0–56.0]
Disease course
Radiological isolated syndrome	2 (3.12)
Clinical isolated syndrome	3 (4.69)
Relapsing–remitting MS	59 (92.19)
MRI features
Gadolinium-enhancing lesions	39 (60.94)
Brain lesions >10	36 (56.25)
Spinal lesion (yes)	44 (67.19)
Disability measures
Switch from first disease-modifying treatments within 1 year	9 (5.7)*
EDSS at diagnosis EDSS < 3 at diagnosis	1.5 [0.0–6.0] 55 (85.94)
EDSS at last follow-up EDSS < 3 at last follow-up	1.5 [0.0–6.5] 56 (87.5)
MSSS at last follow-up	2.85 [0.24–9.59]
ARMSS at last follow-up	3.22 [0.29–8.47]
Biomarkers at diagnosis
NFLs (pg/ml) Serum CSF	29.55 [12.1–262] 1,590.5 [201–35,824]
Gas 6 (ng/ml) Serum CSF	23.49 [12.26–54.65] 7.76 [1.80–32.75]
sAxl (ng/ml) Serum CSF	29.22 [15.42–231.3] 26.38 [7.9–48.19]
sMer (ng/ml) Serum CSF	2.54 [0.0–55.1] 0.0 [0.0–0.0]
sTyro-3 (ng/ml) Serum CSF	3.54 [1.77–9.63] 3.79 [1.71–6.56]

Continuous variables are presented as medians [IQR] and categorical variables as frequencies (%). CSF, cerebrospinal fluid; OB, oligoclonal bands; EDSS, expanded disability status scale, MSSS, multiple sclerosis severity score; ARMSS, age-related multiple sclerosis severity; NFLs, neurofilaments.

*Of the patients, 3/9 stopped/changed the first DMT for side effects, not for efficacy.